BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Prognosis
30 results:

  • 1. The GRAPHS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with immunotherapy.
    Yang Y; Li L; Xu Y; Ouyang J; Zhou Y; Ye F; Huang Z; Zhang W; Zhou A; Zhao X; Cai J; Wang Y; Zhou J; Zhao H
    Radiol Med; 2024 Feb; 129(2):188-201. PubMed ID: 38180570
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Immunohistochemical FAP Expression Reflects
    Spektor AM; Gutjahr E; Lang M; Glatting FM; Hackert T; Pausch T; Tjaden C; Schreckenberger M; Haberkorn U; Röhrich M
    J Nucl Med; 2024 Jan; 65(1):52-58. PubMed ID: 38167622
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Down regulation of Cathepsin W is associated with poor prognosis in pancreatic cancer.
    Khojasteh-Leylakoohi F; Mohit R; Khalili-Tanha N; Asadnia A; Naderi H; Pourali G; Yousefli Z; Khalili-Tanha G; Khazaei M; Maftooh M; Nassiri M; Hassanian SM; Ghayour-Mobarhan M; Ferns GA; Shahidsales S; Lam AK; Giovannetti E; Nazari E; Batra J; Avan A
    Sci Rep; 2023 Oct; 13(1):16678. PubMed ID: 37794108
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Risk Factors of Positive Resection Margin in Hepatectomy for Resectable Ruptured Hepatocellular Carcinoma: Risk Prediction and prognosis.
    Xia F; Zhang Q; Zheng J; Huang Z; Ndhlovu E; Gao H
    J Gastrointest Surg; 2023 Jul; 27(7):1400-1411. PubMed ID: 37095336
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The added value of [
    Liu Q; Shi S; Liu S; Xu X; Hu S; Zhang J; Wang C; Yu X; Song S
    Eur Radiol; 2023 Jul; 33(7):5007-5016. PubMed ID: 36809431
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. 18-Fluoride fluorodeoxyglucose positron emission tomography is impactful in newly diagnosed pancreatic adenocarcinoma.
    Power J; Larcos G
    ANZ J Surg; 2023 Jan; 93(1-2):145-150. PubMed ID: 36582048
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Prospective Phase II Trial of [
    Carlsen EA; Loft M; Loft A; Czyzewska D; Andreassen M; Langer SW; Knigge U; Kjaer A
    J Nucl Med; 2023 Feb; 64(2):252-259. PubMed ID: 35981899
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic cancers Using
    Loft M; Christensen C; Clausen MM; Carlsen EA; Hansen CP; Kroman N; Langer SW; Høgdall C; Madsen J; Gillings N; Nielsen CH; Klausen TL; Holm S; Loft A; Berthelsen AK; Kjaer A
    J Nucl Med; 2022 Dec; 63(12):1871-1879. PubMed ID: 35589407
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review.
    Evangelista L; Zucchetta P; Moletta L; Serafini S; Cassarino G; Pegoraro N; Bergamo F; Sperti C; Cecchin D
    Ann Nucl Med; 2021 Jul; 35(7):767-776. PubMed ID: 34047926
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Elevated Postoperative Levels of Serum C-reactive Protein Are Associated With Shorter Long-term Survival After Resection of Colorectal Liver Metastases, Regardless of the Occurrence of Infectious Complications.
    Shibutani M; Kimura K; Kashiwagi S; Wang EN; Okazaki Y; Maeda K; Hirakawa K; Ohira M
    Anticancer Res; 2021 May; 41(5):2605-2610. PubMed ID: 33952490
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Expression of TIGAR and its correlation with clinicopathology, prognosis, and 18F-FDG PET/CT parameters in patients with resectable pancreatic ductal adenocarcinoma.
    Song Y; Wang PY; Zheng Y; Liu C; Wang XM
    Nucl Med Commun; 2021 May; 42(5):528-534. PubMed ID: 33481504
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Prognostic value of
    Mohamed E; Needham A; Psarelli E; Carroll M; Vinjamuri S; Sanghera B; Wong WL; Halloran C; Ghaneh P
    Eur J Surg Oncol; 2020 Aug; 46(8):1532-1538. PubMed ID: 32070641
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Lung recurrence and its therapeutic strategy in patients with pancreatic cancer.
    Kurahara H; Maemura K; Mataki Y; Tanoue K; Iino S; Kawasaki Y; Idichi T; Arigami T; Mori S; Shinden Y; Higashi M; Ueno S; Shinchi H; Natsugoe S
    Pancreatology; 2020 Jan; 20(1):89-94. PubMed ID: 31787525
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Apparent diffusion coefficient-based histogram analysis differentiates histological subtypes of periampullary adenocarcinoma.
    Lu JY; Yu H; Zou XL; Li Z; Hu XM; Shen YQ; Hu DY
    World J Gastroenterol; 2019 Oct; 25(40):6116-6128. PubMed ID: 31686767
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Significance of
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Kawasaki Y; Arigami T; Mori S; Kijima Y; Ueno S; Shinchi H; Natsugoe S
    Ann Surg Oncol; 2019 Feb; 26(2):644-651. PubMed ID: 30523468
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
    Choi SH; Park SW; Seong J
    Radiother Oncol; 2018 Nov; 129(2):340-346. PubMed ID: 30177371
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Prognostic value of preoperative fluorodeoxyglucose positron emission tomography/computed tomography in patients with potentially resectable pancreatic cancer.
    Omiya Y; Ichikawa S; Satoh Y; Motosugi U; Nakajima N; Onishi H
    Abdom Radiol (NY); 2018 Dec; 43(12):3381-3389. PubMed ID: 30043215
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
    Ghaneh P; Hanson R; Titman A; Lancaster G; Plumpton C; Lloyd-Williams H; Yeo ST; Edwards RT; Johnson C; Abu Hilal M; Higginson AP; Armstrong T; Smith A; Scarsbrook A; McKay C; Carter R; Sutcliffe RP; Bramhall S; Kocher HM; Cunningham D; Pereira SP; Davidson B; Chang D; Khan S; Zealley I; Sarker D; Al Sarireh B; Charnley R; Lobo D; Nicolson M; Halloran C; Raraty M; Sutton R; Vinjamuri S; Evans J; Campbell F; Deeks J; Sanghera B; Wong WL; Neoptolemos JP
    Health Technol Assess; 2018 Feb; 22(7):1-114. PubMed ID: 29402376
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.